Physician profile
Khalid M Abulaban
NPI 1033379458
$878.94
in general payments reported to CMS, 2019-2025
13 companies · $73.53 in 2025
The $73.53 reported for 2025 was less than what a typical Pediatric Rheumatology provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $61.73 · 2021: $12.31 · 2022: $337 · 2023: $119 · 2024: $124 · 2025: $73.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $284.51 | 2019-2025 | |
| Glaxosmithkline, LLC. | $151.20 | 2022 | |
| Amgen INC. | $142.99 | 2019-2023 | Enbrel |
| Sobi, INC | $67.67 | 2020-2024 | |
| Pfizer INC. | $58.76 | 2022 | |
| Abbvie INC. | $34.70 | 2024 | |
| Silvergate Pharmaceuticals, INC. | $29.91 | 2019 | |
| Sandoz INC. | $24.88 | 2023 | Hyrimoz |
| Boston Scientific Corporation | $20.40 | 2025 | Varithena Administration Pack |
| Kiniksa Pharmaceuticals International, Plc | $19.50 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $16.29 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.21 | 2020 | |
| Biomarin Pharmaceutical INC. | $13.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Abulaban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.